Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.60 |
| ▸ | ANPEP | P15144 | 2/20 | 0.60 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.60 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808621 | 1.00 | LAP3 (0.60) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL21570174 | 1.00 | LAP3 (0.60) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5808622 | 1.00 | LAP3 (0.60) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL16431328 | 1.00 | LAP3 (0.60) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL29885081 | 0.97 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL15411968 | 0.89 | CTSD (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL15411970 | 0.89 | CTSD (0.57) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5964673 | 0.89 | LAP3 (0.54) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL29082941 | 0.89 | LAP3 (0.54) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL5964664 | 0.89 | LAP3 (0.54) | LAP3ANPEPRNPEPDNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.